Papillomavirus Vaccines

• 

  Subject Areas on Research

  • A Comparison of Parent- and Provider-Reported Human Papillomavirus Vaccination of Adolescents. 
  • A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. 
  • A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. 
  • A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. 
  • A systematic review of human papillomavirus vaccination among US adolescents. 
  • Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. 
  • Adolescent girls' preferences for HPV vaccines: a discrete choice experiment. 
  • Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. 
  • Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. 
  • Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine. 
  • Assessing university students' sexual risk behaviors as predictors of human papillomavirus (HPV) vaccine uptake behavior. 
  • Associations of health behaviors with human papillomavirus vaccine uptake, completion, and intentions among female undergraduate students. 
  • Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. 
  • Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. 
  • Cervical Cancer Screening. 
  • Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. 
  • Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. 
  • Coincidence analysis: a new method for causal inference in implementation science. 
  • Completeness of human papilloma virus vaccination: A systematic review. 
  • Controversy undermines support for state mandates on the human papillomavirus vaccine. 
  • Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States. 
  • Cost-effectiveness of a potential vaccine for human papillomavirus. 
  • Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. 
  • Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. 
  • Disparities in Provider Recommendation of Human Papillomavirus Vaccination for U.S. Adolescents. 
  • Disparities in healthcare access and utilization and human papillomavirus (HPV) vaccine initiation in the United States. 
  • Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States. 
  • Does Self-Efficacy Mediate the Relationships Between Social-Cognitive Factors and Intentions to Receive HPV Vaccination Among Young Women? 
  • Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women. 
  • Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. 
  • Effects of a randomized controlled trial of a brief, student-nurse led, parent-based sexual health intervention on parental protective factors and HPV vaccination uptake. 
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. 
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. 
  • Examining Associations between Knowledge and Vaccine Uptake Using the Human Papillomavirus Knowledge Questionnaire (HPV-KQ). 
  • Expanding Indications for the Human Papillomavirus Vaccine: One Small Step for the Prevention of Head and Neck Cancer, but One Giant Leap Remains. 
  • Factors Associated With Human Papillomavirus Vaccine Series Completion Among Adolescents. 
  • Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. 
  • Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S. 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • HPV vaccines: now that they're here, how do we maximize their benefit? 
  • Health economics of screening for gynaecological cancers. 
  • Human Papillomavirus Awareness in Haiti: Preparing for a National HPV Vaccination Program. 
  • Human Papillomavirus Vaccination Status and Parental Endorsement Intentions among Undergraduate Student Nurses. 
  • Human Papillomavirus Vaccination and Trends in Cervical Cancer Incidence and Mortality in the US. 
  • Human Papillomavirus-Related Cancer Surveillance, Prevention, and Screening Among Transgender Men and Women: Neglected Populations at High Risk. 
  • Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy? 
  • Human papillomavirus vaccination uptake among Native Hawaiian and Pacific Islander adults in the United States. 
  • Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. 
  • Human papillomavirus vaccine uptake among teens before and during the COVID-19 pandemic in the United States. 
  • Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. 
  • Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. 
  • Increasing HPV vaccination series completion rates via text message reminders. 
  • Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States. 
  • Influence of parent characteristics and disease outcome framing on HPV vaccine acceptability among rural, Southern women. 
  • Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS). 
  • Keen on teen vaccines: improvement of adolescent vaccine coverage in rural North Carolina. 
  • Key stakeholder perspectives on challenges and opportunities for rural HPV vaccination in North and South Carolina. 
  • Medical students' knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer. 
  • Missed Opportunities for Human Papillomavirus Vaccine Initiation in an Insured Adolescent Female Population. 
  • Missed opportunities for adolescent vaccination, 2006-2011. 
  • Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. 
  • Not just a woman's business! Understanding men and women's knowledge of HPV, the HPV vaccine, and HPV-associated cancers. 
  • Paediatricians' attitudes and practices towards HPV vaccination. 
  • Pain in adolescent girls receiving human papillomavirus vaccine with concomitantly administered vaccines. 
  • Parental vaccine concerns in Kentucky. 
  • Pediatricians are more supportive of the human papillomavirus vaccine than the general public. 
  • Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. 
  • Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. 
  • Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states. 
  • Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. 
  • Promoting Strategies to Increase HPV Vaccination in the Pediatric Primary Care Setting. 
  • Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. 
  • Provider response and follow-up to parental declination of HPV vaccination. 
  • Provider-level rates of HEDIS-consistent HPV vaccination in a regional health plan. 
  • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. 
  • Quality of Physician Communication about HPV Vaccine-Letter. 
  • Receipt of Recommended Adolescent Vaccines Among Youth With Special Health Care Needs. 
  • Recommended Adult Immunization Schedule, United States, 2020. 
  • Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. 
  • Rural-Urban Disparities in HPV Vaccination Coverage Among Adolescents in the Central Part of the State of Illinois, USA. 
  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. 
  • Scaling up cervical cancer prevention in Western Kenya: Treatment access following a community-based HPV testing approach. 
  • Self-efficacy and HPV Vaccine Attitudes Mediate the Relationship Between Social Norms and Intentions to Receive the HPV Vaccine Among College Students. 
  • The HPV vaccine: are dosing recommendations being followed? 
  • The current and future role of screening in the era of HPV vaccination. 
  • The design and implementation of an open-source, data-driven cohort recruitment system: the Duke Integrated Subject Cohort and Enrollment Research Network (DISCERN). 
  • The economic impact of HPV vaccines: not just cervical cancer. 
  • The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15-18-year-old adolescent girls compared to user-paid vaccination: a study protocol for a two-arm randomized controlled trial in China. 
  • The impact of human papillomavirus vaccination on cervical cancer prevention efforts. 
  • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. 
  • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. 
  • The role of anticipated regret and health beliefs in HPV vaccination intentions among young adults. 
  • There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination. 
  • Toward Optimal Communication About HPV Vaccination for Preteens and Their Parents: Evaluation of an Online Training for Pediatric and Family Medicine Health Care Providers. 
  • US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening. 
  • Update on immunizations in adults. 
• 

  Keywords of People

  • Myers, Evan Robert, Walter L. Thomas Distinguished Professor of Obstetrics and Gynecology in the School of Medicine, Duke Cancer Institute